CN106841624B - 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 - Google Patents
抗人cd4和抗人cd184单克隆抗体作为标志物的应用 Download PDFInfo
- Publication number
- CN106841624B CN106841624B CN201710061684.XA CN201710061684A CN106841624B CN 106841624 B CN106841624 B CN 106841624B CN 201710061684 A CN201710061684 A CN 201710061684A CN 106841624 B CN106841624 B CN 106841624B
- Authority
- CN
- China
- Prior art keywords
- human
- antibody
- monoclonal antibody
- cell
- connective tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 title claims abstract description 76
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 title claims abstract description 72
- 239000003550 marker Substances 0.000 title abstract description 9
- 208000029523 Interstitial Lung disease Diseases 0.000 claims abstract description 43
- 208000018631 connective tissue disease Diseases 0.000 claims abstract description 31
- 238000003745 diagnosis Methods 0.000 claims abstract description 21
- 238000004393 prognosis Methods 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 43
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 specifically Substances 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 54
- 208000018016 Secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease Diseases 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 230000004199 lung function Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 201000009594 Systemic Scleroderma Diseases 0.000 description 8
- 206010042953 Systemic sclerosis Diseases 0.000 description 8
- 238000011994 high resolution computer tomography Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 101150075764 CD4 gene Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004853 protein function Effects 0.000 description 5
- 230000009325 pulmonary function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000001120 amyopathic dermatomyositis Diseases 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150066398 CXCR4 gene Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001141491 Eumorpha elisa Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710061684.XA CN106841624B (zh) | 2017-01-26 | 2017-01-26 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710061684.XA CN106841624B (zh) | 2017-01-26 | 2017-01-26 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106841624A CN106841624A (zh) | 2017-06-13 |
CN106841624B true CN106841624B (zh) | 2019-02-22 |
Family
ID=59121896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710061684.XA Active CN106841624B (zh) | 2017-01-26 | 2017-01-26 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106841624B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109752548B (zh) * | 2019-02-01 | 2022-05-06 | 广州金域医学检验中心有限公司 | 评估慢性淋巴细胞白血病预后的组合试剂及系统 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1848994A2 (en) * | 2005-02-16 | 2007-10-31 | Wyeth | Methods and systems for diagnosis, prognosis and selection of treatment of leukemia |
DK2160221T3 (da) * | 2007-05-30 | 2011-09-19 | Lilly Co Eli | Cykliske peptid-CXCR4-antagonister |
-
2017
- 2017-01-26 CN CN201710061684.XA patent/CN106841624B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN106841624A (zh) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2635767C2 (ru) | Способы и средства для мониторинга нарушения тканевого гомеостаза в организме | |
JPH06505332A (ja) | 総白血球表面抗原を用いた治療法及び診断法 | |
US20180217158A1 (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
KR101806681B1 (ko) | 스틸씨병 진단용 바이오마커 조성물, 진단 키트 및 진단 방법 | |
US11768202B2 (en) | Method of detecting anti-Ri in a subject with a previous streptococcal infection | |
Zuo et al. | Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren's syndrome | |
Emami et al. | Diagnostic accuracy of IgA anti-tissue transglutaminase in patients suspected of having coeliac disease in Iran | |
CN106841624B (zh) | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 | |
Makhija et al. | Common in vitro tests for allergy and immunology. | |
WO2013107826A2 (en) | Use of cellular biomarkers expression to diagnose sepsis among intensive care patients | |
Kadani et al. | Evaluation of plasma fibrinogen degradation products and total serum protein concentration in oral submucous fibrosis | |
US8609432B2 (en) | Method and kit for detection of autoimmune chronic urticaria | |
Paul et al. | Correlation of serum tissue transglutaminase antibody levels and Marsh grading of duodenal biopsy in patients of celiac disease | |
CN102959398B (zh) | 含有以HpαR为有效成份的肺癌诊断用标记 | |
Ghozzi et al. | Serological screening for celiac disease, by endomysial antibodies, in patients with rheumatoid arthritis. | |
CN110954701A (zh) | 一种肝纤维化或肝硬化的诊断试剂盒 | |
KR102576597B1 (ko) | 면역 노화 평가용 조성물 및 키트 | |
JP5010220B2 (ja) | 造血幹細胞移植療法の施行患者の病態把握方法 | |
KR102621473B1 (ko) | 성인형 스틸병 진단용 바이오마커 조성물 | |
KR102124259B1 (ko) | 신속 면역크로마토그래피법을 이용한 브루셀라균 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주 | |
EP4379375A1 (en) | Classification of connective tissue disease with neurological manifestation using multi-dimensional peripheral blood analysis | |
CN118393143A (zh) | 一种抗人cd4和抗人cd184单克隆抗体的用途 | |
Nugraha et al. | Comparative Diagnostic Value of Dengue Infection Using ELFA and Two Commercial Immuno-Chromatography Tests | |
Fereidouni et al. | Comparison of two flow cytometric methods for detection of human invariant natural killer T Cells (iNKT) | |
Yip | Novel insights into the clinical and immunological aspects of early chronic obstructive pulmonary disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190212 Address after: 201203 Room 237, 2-storey B District, No. 58 Xiangke Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai Patentee after: SHANGHAI FEISHENG BIO-TECH Co.,Ltd. Address before: Room 1301, No. 4, 448 Lane, Liyuan Road, Huangpu District, Shanghai, 200023 Patentee before: Zhuang Leijing |
|
TR01 | Transfer of patent right | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Jiangfeng Inventor after: Wang Kaiwen Inventor after: Zhuang Leijing Inventor before: Zhuang Leijing |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230906 Address after: 201899 No. 1 Chengbei Road, Jiading District, Shanghai Patentee after: Shanghai Jiading District Central Hospital (Jiading District Central Hospital Affiliated to Shanghai Health Medical College and Jiading Branch of Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University) Address before: 201203 Room 237, 2-storey B District, No. 58 Xiangke Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai Patentee before: SHANGHAI FEISHENG BIO-TECH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240109 Address after: 201821 J, building 6, No. 1288, Yecheng Road, Jiading District, Shanghai Patentee after: Fuliusaisi Biotechnology (Shanghai) Co.,Ltd. Address before: 201899 No. 1 Chengbei Road, Jiading District, Shanghai Patentee before: Shanghai Jiading District Central Hospital (Jiading District Central Hospital Affiliated to Shanghai Health Medical College and Jiading Branch of Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University) |